Skip to main content

Table 3 Important human T cell receptors in cancer immunotherapy

From: Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

Receptor family Cluster of Designation Ligands
Activating receptors   
T cell receptor complex CD3 MHC:peptide
Co-receptors   
CD2 CD 2 CD58
CD4 CD4 MHC class II
CD5 CD5 CD72 (?)
CD8 CD8 MHC class I
CD27 CD27 CD70
Activating receptors   
CD28 CD28 B7.1 (CD80), B7.2 (CD86), B7H2 (CD275)
OX40 CD134 OX40L (CD252)
4-1-BB CD137 CD137L
CD40L CD154 CD40
DNAM-1 CD226 PVR (CD155), PVR2 (CD112)
TACI CD267 BAFF (CD257), APRIL (CD256)
BCMA CD269 BAFF (CD257), APRIL (CD256)
ICOS CD278 B7H2 (CD275)
GITR CD357 GITRL (-)
BAFFR n/a BAFF (CD257)
Inhibitory receptors   
B7.1 CD80 PDL-1 (CD274), CD28, CTLA4 (CD152)
CTLA4 CD152 B7.1(CD80), B7.2(CD86), B7H2 (CD275)
CD160 CD160 HVEM (-)
CD200R CD200R CD200
LAG-3 CD223 MHC class II, other?
2B4 CD244 CD48
LIGHT CD258 HVEM (-)
BTLA CD272 HVEM (-)
PDL-1 CD274 PD-1 (CD279)
PD-1 CD279 PD-L1 (CD274), PDL-2 (CD273)
TIM-3 n/a Galectin-9 (-), other?
TIGIT n/a PVR (CD155), PVR2 (CD112)
VISTA (PD-1H) n/a B7H4 (-), other?
B7H4 n/a Unknown
KLRG-1 n/a E-Cadherin (CD324)